Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation is the U.S. pharmaceutical subsidiary of Novartis AG, a Swiss multinational pharmaceutical corporation headquartered in Basel, Switzerland. Novartis AG was founded on December 20, 1996, through the merger of Ciba-Geigy and Sandoz. Novartis AG is publicly traded on the SIX Swiss Exchange (NOVN) and the New York Stock Exchange (NVS). As of late 2025 and early 2026, Novartis AG reported annual revenues of approximately $54.5 billion to $56.6 billion and an employee count of around 75,000 to 84,000 worldwide.

Novartis is an innovative medicines company, having spun off its generics division, Sandoz, in October 2023 to focus on proprietary pharmaceutical products. The company develops and markets drugs in key therapeutic areas including cardiovascular, renal and metabolic diseases, immunology, neuroscience, and oncology. Notable products include Entresto for heart failure, Cosentyx for inflammatory diseases, Kisqali for breast cancer, and Pluvicto for prostate cancer. Novartis also engages in advanced therapeutic modalities such as gene and cell therapies and radioligand therapy.

In patent litigation, Novartis Pharmaceuticals Corporation, as part of Novartis Gene Therapies, Inc. et al., has appeared as a plaintiff in the Patent Trial and Appeal Board. This indicates an active posture in challenging the validity of competitors' patents. In the broader context, Novartis is an operating company that both defends against and asserts patent rights to protect its innovative drug portfolio.

The tracked case, Novartis Gene Therapies, Inc. et al. v. Genzyme Corporation, involves challenges at the Patent Trial and Appeal Board concerning patents related to recombinant adeno-associated virus (AAV) vectors. These patents are pertinent to gene therapy technology, specifically underlying Novartis's drug Zolgensma, which treats spinal muscular atrophy.